Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumours

Official Title

A Phase 1, Multi-centre, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumours That Are Amenable to Direct Injection

Summary:

This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumours that are amenable to direct injection

Trial Description

Primary Outcome:

  • Subject incidence of DLT
Secondary Outcome:
  • Subject incidence of adverse events.
  • Subject incidence of laboratory abnormalities
  • Overall Response Rate (ORR)
  • Duration of Response (DOR)
  • Time to Response (TTR)
  • Time to Progression (TTP)
  • Progression-free Survival (PFS)
  • Overall Survival (OS)
This is a phase 1, multicentre, open-label study of talimogene laherparepvec in pediatric subjects with advanced non-CNS tumours that are amenable to direct injection in the clinical setting. Approximately 18
  • 24 pediatric subjects are expected to be enrolled and treated with at least 1 dose of talimogene laherparepvec into 2 cohorts stratified by age. DLT will be evaluated based on at least 9 DLT-evaluable subjects in cohort A1. The DLT evaluation period is 35 days from the initial administration of talimogene laherparepvec.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society